Curis (CRIS) Projected to Post Earnings on Monday

Curis (NASDAQ:CRIS) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.4360) per share and revenue of $3.2490 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Curis (NASDAQ:CRIS) last released its earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $3.25 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Trading Down 4.2%

Shares of NASDAQ:CRIS opened at $0.56 on Friday. Curis has a 52 week low of $0.52 and a 52 week high of $3.13. The company’s 50 day moving average is $0.95 and its two-hundred day moving average is $1.21. The company has a market cap of $7.63 million, a PE ratio of -0.47 and a beta of 3.02.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CRIS. Jane Street Group LLC grew its holdings in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after buying an additional 10,586 shares during the last quarter. XTX Topco Ltd acquired a new stake in Curis during the 4th quarter worth approximately $26,000. Squarepoint Ops LLC grew its stake in shares of Curis by 46.2% in the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 230,659 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares during the period. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CRIS shares. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Curis in a report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Curis currently has an average rating of “Hold” and a consensus price target of $17.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.